Roche’s Gazyva/Gazyvaro receives US FDA approval for the treatment of lupus nephritis: Basel Wednesday, October 22, 2025, 10:00 Hrs [IST] Roche announced that the US Food and Dr ...

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research at the American College of Rheumatology (ACR) Convergence 2025 meeting in ...

Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody t ...

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro's superiority over standard therapy alone1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to ...